The impact of health technology made simple...

...from the implications of new medical procedures, technologies and policies...

...to measuring their impact on current clinical practices...

...through close collaboration with health care professionals, researchers, and regulators.

Vital Transformation is a small, unique consultancy focused on addressing the challenges of today’s modern healthcare system. We partner with your organisation to help you find answers to hard to solve problems.

  • Real World Economic Analysis

  • Market Research and Access

  • Horizon Scanning

  • Branding

  • Communications

Contact us to learn how Vital Transformation can help your organisation.

LATEST RESEARCH

LATEST COMMUNICATIONS

Our Communication Services

With the continuing pressure placed upon the US biopharma sector from Washington DC, how is the California biopharma ecosystem, arguably the leading hub for innovative biotech worldwide, responding?  In this Vital Health Podcast, we speak with Joseph Panetta to discuss this issue.  Joe is the President & CEO of Biocom California, an organization representing over 1,800 members working in California's life sciences sector to break down barriers to doing business and advocate for innovation.  As the head of Biocom California since 1999, Joe is regarded as a thought leader in biotech and life sciences globally.

Find all our communication projects on Better Science, Better Health

MORE RESEARCH

Medicine adaptive pathways to patients (MAPPs): using regulatory innovation to defeat Eroom’s law

19th May, 2014
Abstract

Eroom’s Law is, literally, Moore’s law in reverse. The pharmaceutical sector invests $50 billion annually in research for new medicines but, “the number of new drugs approved per billion US dollars spent has halved roughly every 9 years since 1950, falling around 80-fold in inflation-adjusted terms”. Pharmaceutical companies have invested enormous sums in new molecular entities (NME) in the areas of unmet medical need identified by the World Health Organization (WHO), but the approval rates from phase I are only 7% for cardiovascular disease, dropping to 4% for Alzheimer’s disease.

Whole-Body Magnetic Resonance Angiography (WBMRA) as a tool for driving efficiency in the cost and treatment of Claudication Comorbities

12th September, 2013
Abstract

Whole-Body Magnetic Resonance Angiography (WBMRA) consists of a contrast-enhanced Magnetic Resonance Angiogram (MRA) scan of the entire body in a single step. In the diagnosis of cardiovascular co-morbidities in Peripheral Arterial Disease (PAD), the utilization of WBMRA can streamline the diagnostic process by minimizing the usage of MRA, CT, and Angiograms. In this work, the potential cost savings to the hospital by using WBMRA in PAD are modeled based on collected data that accounts for all interventions in the radiological department of a set of 50 patients with Claudication in the period 2008–2012 at Ninewells Hospital (NHS Tayside).

VITAL HEALTH PODCASTS

Our podcast series is also available via your favourite channels!

NEWSLETTER

Register now to receive all the latest updates from Vital Transformation including our research, podcasts and more...

VT on X

Our clients include many of the world’s leading health care organisations.

Go to Top